When it comes to NVDA… “acceleration cycles” are the key

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

Malcolm Lloyd-Smith Biography and Net Worth

Insider of Neurocrine Biosciences

Malcolm C. Lloyd-Smith was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and quality assurance. Prior to joining Neurocrine Biosciences, Mr. Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic.

What is Malcolm Lloyd-Smith's net worth?: The estimated net worth of Malcolm Lloyd-Smith is at least $2.33 million as of August 12th, 2022. Mr. Lloyd-Smith owns 18,888 shares of Neurocrine Biosciences stock worth more than $2,328,702 as of November 20th. This net worth estimate does not reflect any other assets that Mr. Lloyd-Smith may own. Learn More about Malcolm Lloyd-Smith's net worth.
How do I contact Malcolm Lloyd-Smith?: The corporate mailing address for Mr. Lloyd-Smith and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Malcolm Lloyd-Smith's contact information.
Has Malcolm Lloyd-Smith been buying or selling shares of Neurocrine Biosciences?: Malcolm Lloyd-Smith has not been actively trading shares of Neurocrine Biosciences during the last ninety days. Most recently, Malcolm Lloyd-Smith sold 21,533 shares of the business's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $105.95, for a transaction totalling $2,281,421.35. Following the completion of the sale, the insider now directly owns 18,888 shares of the company's stock, valued at $2,001,183.60. Learn More on Malcolm Lloyd-Smith's trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 48 times. They sold a total of 592,855 shares worth more than $80,092,533.10. The most recent insider tranaction occured on August, 15th when Director William H Rastetter sold 14,250 shares worth more than $2,090,332.50. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 8/15/2024.

Malcolm Lloyd-Smith Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/12/2022	Sell	21,533	$105.95	$2,281,421.35	18,888
7/27/2021	Sell	16,709	$93.80	$1,567,304.20	15,801
2/10/2021	Sell	1,700	$119.96	$203,932.00	33,610
2/5/2021	Sell	865	$114.15	$98,739.75	29,675
1/26/2021	Sell	1,100	$119.97	$131,967.00	33,013
2/10/2020	Sell	28,969	$104.56	$3,028,998.64	23,200
10/14/2019	Sell	9,956	$90.85	$904,502.60
11/7/2018	Sell	9,000	$110.01	$990,090.00	21,018
5/19/2017	Sell	9,960	$53.63	$534,154.80	17,997
2/7/2017	Sell	116	$44.61	$5,174.76
9/1/2016	Sell	9,000	$50.00	$450,000.00	9,000

Malcolm Lloyd-Smith Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $123.29

$118.91

$124.01

50 Day Range

MA: $118.44

$111.62

$127.17

2 Week Range

Now: $123.29

$108.63

$157.98

Volume

1,404,254 shs

Average Volume

1,060,512 shs

Market Capitalization

$12.48 billion

P/E Ratio

33.05

Dividend Yield

N/A

Beta

0.35